Vanguard Group's Updated Ownership in Vistagen Therapeutics

The Vanguard Group has filed an amendment to its Schedule 13G, reporting its updated ownership in Vistagen Therapeutics Inc. As of September 30, 2025, Vanguard holds 1,687,735 shares, representing 5.5% of the company's common stock. This marks a decrease of 71,907 shares (4.09%) from its previous filing. The total value of the holdings is approximately $6.65 million, an increase of 88.95% from the prior value. Vanguard's clients, including investment companies and managed accounts, have the right to receive dividends or proceeds from the sale of these securities. The filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of influencing the control of the issuer.